← Back to Clinical Trials
Recruiting NCT05351476

NCT05351476 Exercise Training and Fat Metabolism in Postmenopausal Women

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05351476
Status Recruiting
Phase
Sponsor Florida State University
Condition Postmenopausal Symptoms
Study Type INTERVENTIONAL
Enrollment 120 participants
Start Date 2022-05-20
Primary Completion 2027-04-30

Eligibility & Interventions

Sex Female only
Min Age 50 Years
Max Age 75 Years
Study Type INTERVENTIONAL
Interventions
Resistance ExerciseEndurance Exercise

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 120 participants in total. It began in 2022-05-20 with a primary completion date of 2027-04-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Adipose tissue turnover plays a critical role in body weight maintenance, and obesity is underscored by the dysregulated balance between fat breakdown and synthesis. Although there are clear health-related benefits of physical activity, little is known about how resistance exercise, as opposed to endurance exercise, can reduce the risk of metabolic disorders, particularly in women. The goal of the proposed study is to investigate the effectiveness of resistance training to improve basal and stimulated fat metabolism in postmenopausal women with obesity and pre-diabetes, potentially serving as a viable and practical approach to prevent the onset of type 2 diabetes.

Eligibility Criteria

Inclusion Criteria: * Women * Postmenopausal (50-75 yrs.) * Obese (BMI 30-50 kg/m2) * Prediabetes (HbA1c 5.7 - 6.4% or fasting blood glucose 100 to 125 mg/dL, or 2hr OGTT blood glucose 140 to 199 mg/dL) * Sedentary (not performing purposeful exercise training more than 20 minutes per day twice a week) * Non-smokers * No hormone replacement therapy for at least the past two years. Exclusion Criteria: * Engaging in purposeful resistance training or endurance training (\> 20min/day, \> 2 days/week) * Resting blood pressure above 140 mmHg systolic or 90 mmHg diastolic * Type 1 or type 2 diabetes * Medical problems in which exercise is contraindicated, such as chronic infections * History of, or currently presentation with, cancer, cardiovascular or respiratory disease * Uncontrolled thyroid dysfunction, liver or renal dysfunction * Taking any medication affecting lipid metabolism * Musculoskeletal disease or injury that would otherwise prevent engagement in resistance and endurance training * Smokers and those with diagnosed eating disorders

Contact & Investigator

Central Contact

Robert C Hickner, PhD

✉ rhickner@fsu.edu

📞 850-644-1375

Principal Investigator

Robert C Hickner, PhD

PRINCIPAL INVESTIGATOR

Florida State University

Frequently Asked Questions

Who can join the NCT05351476 clinical trial?

This trial is open to female participants only, aged 50 Years or older, up to 75 Years, studying Postmenopausal Symptoms. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05351476 currently recruiting?

Yes, NCT05351476 is actively recruiting participants. Contact the research team at rhickner@fsu.edu for enrollment information.

Where is the NCT05351476 trial being conducted?

This trial is being conducted at Tallahassee, United States.

Who is sponsoring the NCT05351476 clinical trial?

NCT05351476 is sponsored by Florida State University. The principal investigator is Robert C Hickner, PhD at Florida State University. The trial plans to enroll 120 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology